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ABSTRACT 28 
The human respiratory tract pathogen Chlamydia pneumoniae (C. pneumoniae) causing mild to severe 29 
infections have been associated with the development of chronic inflammatory diseases. To understand 30 
the biology of C. pneumoniae infections several studies have investigated the interaction between C. 31 
pneumoniae and professional phagocytes. However, these studies have been conducted under non-32 
opsonizing conditions making the role of opsonization in C. pneumoniae infections elusive. Thus, we 33 
analyzed complement and antibody opsonization of C. pneumoniae and evaluated how opsonization 34 
affects chlamydial infectivity and phagocytosis in human monocytes and neutrophils. 35 
We demonstrated that IgG antibodies and activation products of complement C3 and C4 are deposited 36 
on the surface of C. pneumoniae elementary bodies when incubated in human serum. Complement 37 
activation limits C. pneumoniae infectivity in vitro and have the potential to induce bacterial lysis by 38 
formation of the membrane attack complex. Co-culture of C. pneumoniae and freshly isolated human 39 
leukocytes showed that complement opsonization is superior to IgG opsonization for efficient 40 
opsonophagocytosis of C. pneumoniae in monocytes and neutrophils. Neutrophil-mediated 41 
phagocytosis of C. pneumoniae was crucially dependent on opsonization while monocytes retain minor 42 
phagocytic potential under non-opsonizing conditions. Complement opsonization significantly 43 
enhanced the intracellular neutralization of C. pneumoniae in peripheral blood mononuclear cells and 44 
neutrophils and almost abrogated the infectious potential of C. pneumoniae. ‘ 45 
In conclusion, we demonstrated that complement limits C. pneumoniae infection in vitro by interfering 46 
with C. pneumoniae entry into permissive cells, by direct complement-induced lysis and by tagging 47 
bacteria for efficient phagocytosis in both monocytes and neutrophils. 48 
 49 
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INTRODUCTION 50 
Chlamydia pneumoniae (C. pneumoniae) is a human pathogen frequently causing mild respiratory 51 
symptoms during infection that usually resolves spontaneously but can cause severe, long-lasting 52 
atypical pneumonia and has been associated with the development of several chronic disease conditions 53 
including atherosclerosis and asthma (1, 2). C. pneumoniae is an obligate intracellular Gram-negative 54 
bacterium with a unique biphasic developmental cycle. The bacterium alternates between the 55 
extracellular infectious elementary body (EB) and the intracellular non-infectious reticular body (RB). 56 
During infection, C. pneumoniae EBs engage airway epithelium and induce their own uptake by 57 
secreting pre-formed effectors into the host cell cytoplasm by the type-III secretion system (3). 58 
Intracellularly, the EBs transform into RBs and start replicating in a modified vacuole called an 59 
inclusion. After 48-72 hours RBs start to divide asynchronously and EBs are formed and released from 60 
the host cell by cell lysis or by membrane extrusion (4).    61 
Upon infection, C. pneumoniae EBs first encounter airway epithelial cells and alveolar macrophages 62 
which respond to infection by secreting inflammatory mediators stimulating vascular endothelium 63 
activation and immune cell chemotaxis (5). Neutrophil granulocytes are the first immune cells to 64 
transmigrate from the blood stream into the alveolar space and subsequently signal for mononuclear 65 
cell recruitment and infiltration (6, 7). Thus, neutrophils and monocytes comprise an early cellular 66 
defense against C. pneumoniae and the interaction between extracellular chlamydial EBs and these 67 
phagocytes likely determines the course of the infection. Multiple studies have proposed that C. 68 
pneumoniae can evade intracellular killing mechanisms in both monocytes and neutrophils and thereby 69 
use these cells as cellular vectors for extrapulmonary dissemination potentially causing chronic disease 70 
(8–10). However, these pro-survival mechanisms may be altered by the route of bacterial ingestion 71 
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since engagement with different phagocytic receptors activates different intracellular signaling and 72 
trafficking pathways. 73 
It was previously shown that phagocytic uptake of the intracellular bacterium Mycobacterium 74 
tuberculosis (M. tuberculosis) through complement receptors or the mannose receptor protects the 75 
bacterium from intracellular killing by delaying phagosome maturation (11, 12). On the contrary, 76 
uptake of antibody opsonized M. tuberculosis trough Fcγ-receptors causes rapid phagosome maturation 77 
and phagolysosomal fusion leading to reduced infection outcome. Thus, opsonin-directed phagocytosis 78 
is a critical factor determining the intracellular fate of M. tuberculosis and similar mechanisms could be 79 
involved in C. pneumoniae infections and pathogenesis, despite these pathogens being very different in 80 
nature. 81 
The complement system consists of more than 30 soluble and membrane-bound proteins that works in 82 
a cascade-like manner to induce anti-microbial effector functions including opsonization, chemotaxis 83 
and cell lysis. The cascade process is initiated within minutes of engagement (13) and proceeds through 84 
three separate activation pathways: Classical- (recognition of antibody complexes), lectin- (recognition 85 
of carbohydrate moieties), and alternative pathway (spontaneous hydrolysis of C3) (14). Following 86 
activation, complement C4 and C3 are proteolytically cleaved into small soluble C4a/C3a fragments (9 87 
kDa each) and large C4b/C3b fragments (75 kDa and 110 kDa, respectively) that attach covalently to 88 
the activating surface and opsonize the microbe for phagocyte detection. C3b can be further cleaved 89 
into iC3b, C3dg or C3d, which are all potent opsonins recognized by different complement receptors 90 
on phagocytic cells (14). The final stage of the complement cascade includes cleavage of complement 91 
C5 and generation of a multimeric membrane-spanning C5b-9 complex (membrane attack complex, 92 
MAC) that induces pore formation and cell lysis (14). 93 
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During primary infection, C. pneumoniae engages the complement system in the alveolar space. 94 
Although alveolar complement concentration and activity is reduced compared to concentrations and 95 
activity seen in serum, the system is sufficiently functional to opsonize M. tuberculosis with 96 
complement C3 activation products (15, 16). Primary infection leads to C. pneumoniae-specific IgG 97 
production, but these antibodies offers limited protection against C. pneumoniae since reinfections are 98 
frequently observed (17). Thus, during secondary infections both antibodies and complement are 99 
present in the alveolar space, which have the potential to modulate the intracellular fate of C. 100 
pneumoniae in phagocytes and hence the outcome of the infection. 101 
To further characterize the pathogenesis of C. pneumoniae during primary and secondary infections we 102 
investigated how complement- and antibody opsonization affect phagocytosis and intracellular survival 103 
of C. pneumoniae in human monocytes and neutrophils. 104 
 105 
 106 
 107 
 108 
 109 
 110 
 111 
 112 
 113 
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RESULTS 114 
Complement- and antibody opsonization of C. pneumoniae  115 
To examine the role of opsonization and phagocytosis during C. pneumoniae infections, we first 116 
screened the serum from 10 healthy donors for IgG antibodies against C. pneumoniae and found that 117 
nine out of ten donors were positive for IgG against C. pneumoniae. Serum from one seropositive 118 
individual and serum from the only identified seronegative individual were used in all further 119 
experiments. These sera are called immune serum and non-immune serum, respectively, throughout 120 
this paper. 121 
Different cleavage fragments of complement C3 and C4 are known to bind and opsonize bacteria for 122 
phagocytic recognition. C3 deposition on C. pneumoniae has only been investigated by flow cytometry 123 
using an antibody recognizing various C3 cleavage forms (18). Thus, the exact C3 opsonins that bind 124 
the C. pneumoniae surface remain unknown. In addition, complement C4 deposition has never been 125 
investigated on C. pneumoniae. We therefore analyzed the deposition of these complement components 126 
on purified C. pneumoniae EBs using immunoelectron microscopy (IEM) and western blotting. 127 
Figure 1A demonstrates that complement C3 is abundantly deposited on the chlamydial surface when 128 
incubated in non-immune serum (NHS-). Very limited C3 deposition was observed in heat-inactivated 129 
serum (HIHS-) (Fig. 1B) suggesting that C3 deposition was due to activation of the complement system 130 
and not due to unspecific antibody binding  This observation was confirmed by quantification of gold 131 
particles showing a median gold-binding ratio of 21.8 in NHS- (12.1-20.9) vs. 1.9 in HIHS- (1.2-2.6) 132 
(Fig. 1C). 133 
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These observations were confirmed by western blot analysis demonstrating solid deposition of C3 in 134 
NHS-, but not in HIHS- (Fig. 1D). Several high molecular bands (above 110 kDa) are seen on the 135 
western blot, indicating cleavage of the alpha chain of native C3 and covalent attachment of C3 136 
fragments to chlamydial surface structures (Fig. 1D). The 40 kDa fragment shown in Fig. 1D 137 
corresponds to the α’2 chain of C3, demonstrating deposition of the potent opsonin iC3b.  138 
Interestingly, we also demonstrated deposition of C4 on the chlamydial surface when incubated in 139 
NHS- (Fig. 1E), but not in HIHS- (Fig. 1F). Compared to C3, C4 was more sporadically deposited on 140 
the chlamydial surface indicated by a lower bacteria-to-background ratio for C4 (Fig. 1E+G). The 141 
observations were confirmed by western blot analysis which demonstrated deposition of the C4b 142 
opsonin. C4b deposition is indicated by the emergence of high molecular bands suggesting cleavage 143 
and exposure of the thioester group in the alpha chain of C4 along with the presence of the C4 beta- (70 144 
kDa) and gamma chains (35 kDa) (Fig. 1H). These observations suggest involvement of the lectin-145 
mediated pathway since the non-immune serum tested negative for both anti-C. pneumoniae IgG and 146 
IgM making classical-mediated C4 activation unlikely. 147 
To evaluate opsonization during secondary infection we incubated C. pneumoniae EBs in immune-148 
serum and investigated both antibody- and complement opsonization. Immunofluorescence microscopy 149 
demonstrated that immune serum reacted with individual chlamydial organisms located in perinuclear 150 
inclusions in infected HeLa cells (Fig. 2A). The IgG antibodies reacted with the surface of RBs 151 
indicated by the ring-shaped structures surrounding a DNA core (Fig, 2A). As expected, non-immune 152 
serum did not react with the chlamydial inclusions (Fig. 2B). These observations were made on fixed 153 
and permeabilized cells and may not accurately reflect native surface labeling.  154 
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Thus, to investigate native antibody labeling and to determine if antibodies in immune-serum also bind 155 
C. pneumoniae EBs, we incubated purified C. pneumoniae EBs with immune-serum and evaluated IgG 156 
binding to the surface by IEM. Gold-conjugated anti-human IgG antibodies bind to the surface of 157 
chlamydial EBs when incubated in immune-serum (Fig. 2C), while only few gold particles were 158 
associated with chlamydial EBs when incubated in non-immune serum (Fig. 2D). Quantitative analysis 159 
demonstrated a median gold-binding ratio of 27.1 (23.6-39.1) in HIHS+ vs. 1.1 (0.6-2.5) in HIHS-, 160 
showing that the limited bacterial gold deposition observed in non-immune serum equals the 161 
background gold deposition (Fig. 2E). Thus, human C. pneumoniae IgG antibodies present in serum 162 
interact with epitopes located both on fixed RBs (Fig. 2A) and native EBs (Fig. 2C+E). 163 
Next, we wanted to investigate if anti-C. pneumoniae IgG affects complement activation and 164 
deposition on the chlamydial surface. Complement C3 was heavily deposited when C. pneumoniae 165 
were incubated in NHS+, but not in HIHS+ (Fig. 2F-H). Similar levels of C3 deposition between 166 
immune serum and non-immune serum were observed (median ratios: NHS-: 21.8 vs. NHS+: 23.8) 167 
suggesting a negligible role of IgG in complement C3 deposition (Fig. 1A+C and Fig 2F+H).  168 
As expected, complement C4 was deposited on C. pneumoniae incubated in NHS+, but not in HIHS+ 169 
(Fig. 2J-L). More complement C4 deposition was observed in immune serum, in the presence of IgG, 170 
compared to non-immune serum (median ratios: NHS-: 3.5 vs. NHS+: 27.5) suggesting increased 171 
classical complement activation. 172 
Increased complement C4 deposition in immune serum compared to non-immune serum was also 173 
indicated by western blot analysis demonstrating more intense C4 bands when bacteria were incubated 174 
in immune-serum (Fig. 2M vs. Fig. 1H). Several high molecular bands were observed suggesting 175 
cleavage of the alpha chain of C4 and covalent attachment of C4b to the bacterial surface. In addition, 176 
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the cleaved alpha chain (a’ chain) was observed around 80 kDa suggesting non-covalent attachment of 177 
C4b (Fig. 2M).    178 
In summary, C. pneumoniae is opsonized by iC3b and C4b in the absence of anti-C. pneumoniae IgG. 179 
C. pneumoniae IgG is able to bind both EBs and RBs leading to increased C4b deposition on purified 180 
EBs. 181 
 182 
Complement-mediated bacterial lysis  183 
We wanted to investigate if the initial binding of complement and antibodies alone could interfere with 184 
reproductive infection of C. pneumoniae, since antibody binding and complement activation precede 185 
immune cell infiltration.   186 
Electron microscopy revealed that most chlamydial organisms were intact after 30 minutes of 187 
incubation in serum, demonstrating no signs of bacterial lysis (Fig. 3A). However, few bacteria showed 188 
signs of complement-mediated lysis indicated by disruption of normal bacterial morphology together 189 
with pore-forming structures (Fig. 3B, arrowheads). Thus, we aimed to investigate if the complement 190 
cascade proceeds through the terminal complement pathway leading to MAC-induced bacterial lysis in 191 
these cases. Chlamydial organisms were incubated in non-immune- and immune serum and 192 
immunogold-labeled using a monoclonal antibody, recognizing a neoepitope of the C5b-9 complex. As 193 
shown in Fig. 3C, C5b-9 is asymmetrically deposited on disintegrated chlamydial organisms and is 194 
located in close proximity to 10 nm pore-like structures indicating MAC formation and MAC-induced 195 
lysis. Bacteria incubated in heat-inactivated serum showed no signs of bacterial lysis (Fig. 3D).  MAC 196 
formation was observed in both immune- and non-immune serum, but more gold was observed in 197 
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NHS+ samples (median ratio: 34.5 (12.0-72.4)) compared to NHS- samples (median ratio: 12.1 (6.0-198 
36.2)), suggesting that serum IgG promotes formation of C5b-9 complexes. Interestingly, most gold-199 
labeled bacteria appeared healthy, with normal morphological features, and with no signs of bacterial 200 
lysis. These observations suggest that non-lytic C5b-9 complexes are formed on the chlamydial 201 
surface. Chlamydial organisms with altered morphology and signs of bacterial lysis appeared generally 202 
larger than unaffected chlamydiae possibly representing intermediate- or reticular bodies inevitably 203 
located within the EB fraction during the EB purification process. These observations imply that lytic 204 
C5b-9 formation occurs primarily on intermediate- or reticular bodies but leaving EBs unaffected. 205 
Thus, some C. pneumoniae organisms are sensitive to complement-mediated lysis in both immune and 206 
non-immune serum.  207 
Our observations show that complement fragments and antibodies deposit on almost all C. pneumoniae 208 
EBs while only few bacteria are directly killed by complement-mediated lysis. We therefore asked if 209 
opsonin deposition on apparently intact Chlamydia EB had any effect on chlamydial infectivity. To 210 
answer this question, we tested the ability of immune- and non-immune serum to neutralize chlamydial 211 
infection in HeLa cells by enumerating inclusion forming units (IFU) in each experimental condition. 212 
Figure 4 shows that complement had a significant impact on chlamydial infectivity. Only 0.38% ± 0.2 213 
(mean ± SD) and 1.19% ± 0.72 of the initial inoculum was recovered after incubation in immune- 214 
(NHS+) and non-immune serum (NHS-), respectively. These observations indicate that the 215 
combination of complement and antibodies more efficiently reduces chlamydial infectivity than 216 
complement alone, but the difference was not statistically significant. When serum was heat-inactivated 217 
19.1% ± 6.7 and 44.7% ± 5.8 (Fig. 4) of inoculum was recovered demonstrating that complement 218 
significantly inhibits C. pneumoniae infectivity. The difference between heat-inactivated immune- 219 
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(HIHS+) and non-immune serum (HIHS-) further suggests that antibodies alone can reduce C. 220 
pneumoniae infectivity. To confirm this observation, we supplemented heat-inactivated non-immune 221 
serum (HIHS-) with the IgG fraction from a seropositive donor and evaluated chlamydial infectivity. 222 
As shown in Figure 4, supplementing non-immune serum with anti-C. pneumoniae IgG (HIHS-+IgG) 223 
significantly reduced chlamydial infectivity compared to non-immune serum alone confirming that 224 
anti-C. pneumoniae IgG reduces infectivity of C. pneumoniae. These data demonstrate that both 225 
antibody-, but especially complement opsonization have profound impact on C. pneumoniae 226 
infectivity. 227 
 228 
Complement-mediated phagocytosis of C. pneumoniae  229 
As demonstrated above, neither complement- nor antibody opsonization completely abrogates 230 
chlamydial infectivity. We therefore aimed to investigate how phagocytes participate in the clearance 231 
of opsonized C. pneumoniae. To quantitatively evaluate the role of opsonization in phagocytic uptake 232 
during primary and secondary infections, we analyzed the uptake of opsonized and non-opsonized C. 233 
pneumoniae EB in monocytes and neutrophils by flow cytometry. Intracellular staining of cells for 234 
flow cytometry is troublesome as it requires cell permeabilization which causes considerable changes 235 
to physical characteristics of the cells.  To avoid permeabilization C. pneumoniae organisms were 236 
labeled by FITC and uptake of FITC-labeled bacteria and FITC-labeling specificity were evaluated by 237 
confocal microscopy.  238 
Figure S1 shows that FITC-labeled organisms appear small (around 0.5 µm) and round in accordance 239 
with the morphology of chlamydial EBs. To confirm the intracellular location of these FITC-signals, 240 
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monocytes were stained for the cytoplasmic protein S100A8 to visualize the cell cytoplasm (Fig. S1B). 241 
As demonstrated in Fig. S1C all FITC-positive organisms are located inside the cell cytoplasm.  242 
FITC-labeling is a rather unspecific fluorescent labeling technique since the isothiocyanate group reacts 243 
with primary amine groups. Thus, to evaluate whether the FITC-signal in Fig. S1 originates from 244 
chlamydial organisms and not contaminants like cell debris from the chlamydial isolation procedure, 245 
we stained FITC-labeled chlamydiae with a monoclonal antibody against chlamydial LPS. As 246 
demonstrated in Fig. S1D+F all FITC-positive structures reacted with the anti-Chlamydia LPS antibody 247 
confirming that all FITC-positive structures are chlamydial organisms. Thus, FITC-labeling of C. 248 
pneumoniae is efficient and specific and the FITC-labeled bacteria locate inside the cells enabling the 249 
bacteria to be used in a flow cytometric assay.  250 
To analyze the effect of opsonization on phagocytosis of C. pneumoniae, isolated leukocytes were 251 
incubated with FITC-labeled C. pneumoniae in 30 min under different opsonizing conditions and 252 
subjected to flow cytometry analysis. To quantify the uptake, monocyte and neutrophil cell populations 253 
were gated as demonstrated in Fig. S2. Both cell types were gated based on forward- and side-scatter 254 
characteristics and monocytes were additionally gated based on CD14 surface expression.  255 
We first analyzed the role of complement-mediated opsonophagocytosis to experimentally mimic the 256 
infection conditions during primary infection. Thus, phagocytic uptake was quantified in medium 257 
containing either normal non-immune serum (NHS-) or heat-inactivated non-immune serum (HIHS-).  258 
As depicted in Fig. 5A+B, phagocytosis of C. pneumoniae in both monocytes and neutrophils is much 259 
more efficient in NHS- compared to HIHS- suggesting an important role for complement opsonization 260 
in phagocytosis of C. pneumoniae. Interestingly, neutrophil-mediated phagocytosis was almost absent 261 
under non-opsonizing conditions (Fig 5B, HIHS-), suggesting that opsononization is paramount for 262 
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neutrophil phagocytosis of C. pneumoniae while monocytes exploit opsonin-independent phagocytic 263 
pathways. 264 
 265 
Phagocytosis in the presence of anti-chlamydial antibodies 266 
We demonstrated that monocyte- and especially neutrophil-mediated phagocytosis of C. pneumoniae 267 
were critically dependent on complement opsonization. Complement activation and activity in the 268 
alveolar space is reduced compared to serum and is primarily dependent on classical complement 269 
activation (15, 16). Thus, we sought to investigate whether anti-C. pneumoniae antibodies could 270 
mediate efficient phagocytosis or potentiate complement-mediated phagocytosis as both mechanisms 271 
may be important to understand the biology of C. pneumoniae reinfections.  272 
By comparing the heat-inactivated immune serum (Fig 5C+D, HIHS+) with heat-inactivated non-273 
immune serum (Fig 5A+B, HIHS-) it is evident that antibody opsonization increased phagocytic uptake 274 
of C. pneumoniae in both monocytes (3-fold increase) and especially in neutrophils (17-fold increase), 275 
however this effect was significantly lower compared to complement alone. To confirm these 276 
observations, we purified the IgG-fraction from immune serum and supplemented HIHS- with purified 277 
IgG. As demonstrated in Fig. 5E+F, supplementing non-immune serum with the IgG-fraction from 278 
immune serum increased the phagocytic uptake in both monocytes and neutrophils, confirming that the 279 
observed differences are due to anti-C. pneumoniae antibodies. We could not assess whether the 280 
presence of IgG potentiated complement-mediated phagocytosis since both monocyte and neutrophil 281 
cell populations were saturated with bacteria when complement competent serum was used (Fig. 5A-D, 282 
NHS+/-). We therefore re-analyzed these samples using C. pneumoniae at MOI=1 and showed that 283 
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monocytes and neutrophils more efficiently ingest C. pneumoniae when both complement and IgG 284 
antibodies are present (Fig. 5G+H). 285 
 286 
Intracellular survival of ingested bacteria 287 
C. pneumoniae is ingested through both complement- and antibody dependent mechanisms. Evidence 288 
from other intracellular bacteria shows that the intracellular fate of ingested bacteria is highly 289 
dependent on the route of uptake, and it is therefore important to study the intracellular fate of C. 290 
pneumoniae under the opsonizing conditions we have demonstrated here. 291 
To evaluate the intracellular fate of ingested bacteria, PBMCs and neutrophils containing opsonized 292 
and non-opsonized bacteria were lysed by ultrasonication and liberated bacteria were used to infect 293 
HeLa cell monolayers. 294 
Statistically significantly less IFU were recovered when bacteria were ingested by PBMCs in the 295 
presence of immune serum (NHS+: 45 ±19 IFU/µl) and non-immune serum (NHS-: 70 ±16 IFU/µl) 296 
compared to bacteria ingested in media supplemented with heat-inactivated immune serum (HIHS+: 297 
315 ±49 IFU/µl) and non-immune serum (HIHS-: 452 ±25 IFU/µl) (Fig. 6A). Similar results were 298 
obtained for neutrophils with 99 ±4 IFU/µl and 141 ± 32 IFU/µl recovered IFU in immune- and non-299 
immune serum, respectively (Fig. 6B). Serum heat-inactivation caused a statistically significant 300 
increase in IFU recovery from both immune serum (Fig. 6B, HIHS+: 452 ±139 IFU/µl) and non-301 
immune serum (Fig. 6B, HIHS-: 1151 ±259 IFU/µl).  Although more bacteria are present 302 
intracellularly in cells incubated in NHS compared to HIHS (Figure 5A-D) more reproductive bacterial 303 
organisms can be recovered from cells in HIHS. These data suggest that complement not only facilitate 304 
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rapid and efficient uptake of C. pneumoniae, but also mediates effective intracellular neutralization.  305 
We also observed statistically significant less IFU recovered from bacteria ingested in the presence of 306 
heat-inactivated immune serum (HIHS+) compared to heat-inactivated non-immune (HIHS-) in both 307 
cell types (Fig. 6A+B) suggesting that antibodies also play a role in bactericidal activity against C. 308 
pneumoniae.  309 
Studies performed on M. tuberculosis suggest that bacterial uptake by complement receptors delays 310 
phagosomal maturation and phagolysomal fusion thereby facilitating intracellular bacterial survival. 311 
Our results suggest the opposite; that complement-mediated uptake leads to rapid intracellular 312 
neutralization of C. pneumoniae. We therefore tested whether C. pneumoniae were targeted to 313 
lysosomal compartments in monocytes after complement-mediated ingestion. Figure 6C-E shows that 314 
C. pneumoniae localizes within LAMP1-positive vesicular structures in monocytes after 30 min 315 
incubation in media supplemented with non-immune serum (NHS-). Staining of mock infected cells 316 
demonstrates that FITC-signal in LAMP1-positive structures originates from chlamydial organisms 317 
(Fig. 6F). Thus, complement-mediated uptake of C. pneumoniae in monocytes directs ingested bacteria 318 
to lysosomal compartments.     319 
 320 
 321 
 322 
 323 
 324 
 325 
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DISCUSSION 326 
In the present study, we demonstrated that C. pneumoniae EBs are opsonized with both IgG and the 327 
complement opsonins iC3b and C4b when incubated in human serum. We showed that complement 328 
activation limits C. pneumoniae infection in multiple ways by interfering with C. pneumoniae entry 329 
into permissive cells, by direct MAC-induced lysis and by tagging bacteria for efficient phagocytosis 330 
by both monocytes and neutrophils.  331 
The activation and deposition of complement C3 and the terminal complement complex on C. 332 
pneumoniae demonstrated in this study were previously shown by Cortes and colleagues (18). 333 
Interestingly, using electron microscopy, we observed C5b-9 deposition without pore-formation and 334 
bacterial lysis. C5b-9 complexes associated with pore-like structures and altered bacterial morphology 335 
were primarily observed on reticular- and intermediate bodies. Thus, our observations suggest that 336 
extracellular EBs may be resistant to MAC-induced lysis. It is likely, that the cysteine-rich proteins in 337 
the highly cross-linked chlamydia outer membrane of EBs provide a physical barrier that hinders 338 
components of the terminal complement complex to interact with the outer membrane lipid bilayer. 339 
Alternatively, MAC formation could be inhibited by recruitment of host-derived complement 340 
regulators to the EB surface. Thus, it was previously demonstrated that C. trachomatis binds the MAC-341 
inhibitor vitronectin, however, it was not investigated if vitronectin modulates complement deposition 342 
on the chlamydial surface (19).    343 
Cortes et al. concluded that properdin and alternative complement activation was indispensable for C3b 344 
deposition and complement-mediated neutralization. Interestingly, we found that complement C4 is 345 
deposited on the surface of C. pneumoniae. Deposition of complement C4 in both immune- and 346 
nonimmune serum suggests that also the lectin-mediated activation pathway is involved in C. 347 
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pneumoniae induced complement activation. This observation is supported by previous studies 348 
demonstrating that different lectins can bind the surface of C. pneumoniae (20, 21). Moreover, 349 
quantification of gold-labeling and semi-quantitative western blot analysis suggested that more C4 was 350 
deposited in immune serum compared to non-immune serum, indicating activation of the classical 351 
pathway. This is supported by the finding that IgG1 is the predominant IgG subclass raised against C. 352 
pneumoniae and to a lesser extend IgG3 and both IgG1 and IgG3 are efficient complement activators 353 
(22). The IgG subclasses raised against C. pneumoniae may also explain why we observe an IgG-354 
dependent inhibition of C. pneumoniae infectivity in HeLa cells (Fig. 4). Studies on C. trachomatis 355 
showed that HeLa cells express FcγRIII and that Fc-mediated endocytosis through this receptor 356 
promotes reproductive infection of C. trachomatis (23, 24). It is likely that C. trachomatis is more 357 
prone to FcγRIII-mediated uptake compared to C. pneumoniae since IgG3 is the predominant IgG 358 
subclass raised against C. trachomatis (22). Thus, the IgG subclass distribution seems important for the 359 
infectivity and reproductive outcome of Chlamydia spp. in vitro. 360 
A possible explanation for the discrepancies between our results and the findings by Cortes et al. could 361 
be that classical- and/or lectin-mediated activation pathways are abrogated at the C4 level leading to 362 
pathway termination before C3 cleavage. C4 binding protein (C4bp), a fluid-phase negative 363 
complement regulator, can terminate complement activation at the C4 level by inducing C4b cleavage 364 
and C2a dissociation from the classical C3 convertase (25). Several bacterial pathogens are able to 365 
recruit and bind C4bp leading to complement resistance, but this has not yet been demonstrated for 366 
chlamydial organisms (26, 27). 367 
The alternative activation pathway seems important for C. pneumoniae-induced complement activation 368 
in vitro but the significance of this pathway during in vivo lung infections is still elusive. In the lungs, 369 
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complement activation proceeds primarily through the classical pathway and alternative complement 370 
activation fails to activate and deposit C3 on both mycobacteria and streptococci in bronchoalveolar 371 
lavage fluid (15, 28). It remains uncertain whether C. pneumoniae is opsonized in the alveolar space of 372 
the lungs, but the classical complement activation is functional, and during secondary infection 373 
complement activating IgG is present in the alveolar space (15). 374 
We show that complement efficiently facilitates phagocytosis of C. pneumoniae in both monocytes and 375 
neutrophils and that most opsonized bacteria are unable to cause reproductive infection when liberated 376 
from phagocytes. Complement receptor 3 (CR3, CD11b/CD18) recognizes different C3 cleavage 377 
fragments including iC3b identified on C. pneumoniae EBs here. CR3 is, together with Fcγ-receptors, 378 
the most important phagocytic receptor and is widely expressed on both monocytes and neutrophils. It 379 
is, therefore, likely that complement-mediated phagocytosis takes place via CR3 leading to intracellular 380 
destruction. This is different from CR-mediated uptake of other intracellular bacteria. CR-mediated 381 
uptake of M. tuberculosis into human monocytes and macrophages allow safe entrance by delaying 382 
phagosomal maturation and phagolysosomal fusion (11). We observed that C. pneumoniae is rapidly 383 
targeted to LAMP1-positive intracellular compartments showing efficient phagosomal trafficking 384 
facilitating intracellular neutralization of the chlamydial reproductive potential. Thus, safe entrance into 385 
host cells through CR-mediated phagocytosis is not a conserved mechanism for all intracellular 386 
bacteria. This is supported by the observation that the facultative intracellular bacterium Francisella 387 
tularensis (F. tularensis) fails to escape phagosomal trafficking in murine bone-marrow macrophages 388 
when opsonized with either complement or IgG (29). Knockout of CD11b, a subunit of the 389 
heterodimeric CR3, leads to phagosomal escape with cytosolic localization of F. tularensis, supporting 390 
that CR3 plays opposing roles during experimental infections with different intracellular bacteria (29).   391 
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Direct interaction between opsonized bacteria and phagocytic opsonin-receptors provides one 392 
explanation for the increased phagocytic uptake and intracellular neutralization observed here. 393 
Phagocytic priming by the complement anaphylatoxins C3a and C5a may provide another likely 394 
explanation. In an in vivo C. psittaci lung infection model C5aR-/- mice displayed slightly worsened 395 
clinical score compared to WT during early stage infection (30). The same authors later demonstrated 396 
that C3a and its receptor C3aR are critically involved in anti-chlamydial immunity in the same C. 397 
psittaci lung infection model (31). Both receptors are expressed on monocytes and neutrophils and can 398 
potentiate phagocytic functions by inducing both an increased surface expression of complement 399 
receptors and induce a hostile intracellular environment (32, 33). C5a induces increased surface 400 
expression of CD11b and increased phagocytosis of Escherichia coli (E. coli) in neutrophils (34) and 401 
can also potentiate intracellular killing of E. coli by increasing the oxidative burst in a whole blood 402 
assay (35). 403 
In addition, priming neutrophils with C5a leads to translocation of CR1 containing secretory vesicles to 404 
the cell surface (36, 37). CR1 recognizes the activation products C3b and C4b together with several 405 
other complement-related proteins (38). We demonstrate for the first time, that C4b is deposited on the 406 
surface of C. pneumoniae and hence, C5a-induced translocation of CR1 to the plasma membrane may 407 
induce increased bacterial phagocytosis. However, the role of C4b in opsonophagocytosis remains 408 
elusive.  409 
We demonstrated that C. pneumoniae ingested in the presence of complement-competent serum had 410 
impaired ability to cause reproductive infection in HeLa cells compared to bacteria ingested under non-411 
opsonizing conditions. Intracellular survival and replication of C. pneumoniae within phagocytes have 412 
previously been evaluated in several in vitro studies; however, these have been conducted under 413 
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various experimental conditions. Both C. pneumoniae and C. trachomatis are able to replicate in 414 
human neutrophils when ingested under non-opsonizing conditions (10, 39). Rajeeve et al. showed that 415 
C. trachomatis uses the chlamydial protease-like activating factor (CPAF) to inhibit neutrophil 416 
activation and cell death thereby creating a replicative environment (39). Since CPAF is highly 417 
conserved among chlamydiae, C. pnuemoniae may use a similar CPAF-dependent mechanism to 418 
survive and replicate in neutrophils. 419 
Similarly, co-incubating monocytes and C. pneumoniae under non-opsonizing conditions leads to 420 
recovery of chlamydial progeny up until 48 hours post infection (9, 40) suggesting that opsonin-421 
independent uptake also facilitates C. pneumoniae survival in monocytes. This idea was further 422 
supported by the observation that differentiated macrophages support intracellular replication of C. 423 
pneumoniae. Differentiated macrophages, but not peripheral blood monocytes, express the mannose 424 
receptor (MR) which facilitate intracellular survival of M. tuberculosis, and MR has also been linked to 425 
phagocytic uptake of chlamydial organisms (12, 41, 42).  Others used commercially available human 426 
serum from AB blood type donors in the infection medium combined with centrifugation. These 427 
studies were unable to recover chlamydial progeny after 6 and 48 hours, but detected 16S rRNA 428 
suggesting metabolic, but not replicative activity (8, 43). However, neither complement functional 429 
activity nor serostatus were evaluated for these sera making it difficult to draw any conclusions on the 430 
role of opsonization. We demonstrated that both complement- and IgG-opsonization potentiates 431 
phagocytosis and intracellular killing of C. pneumoniae suggesting that the uptake mechanism is 432 
important for the intracellular fate of C. pneumoniae previously demonstrated for other chlamydial 433 
organisms (44).     434 
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Here we demonstrated that complement opsonization and to a lesser extend IgG opsonization inhibits 435 
C. pneumoniae progeny infection and facilitates C. pneumoniae uptake in human monocytes and 436 
neutrophils. Ingested bacteria are rapidly trafficked to destructive intracellular compartments and 437 
eliminated showing that opsonization and phagocytosis are efficient means of controlling extracellular 438 
C. pneumoniae organisms. Thus, opsonization is a critical factor to include in future in vitro studies 439 
exploring the interaction between C. pneumoniae and human phagocytes.   440 
 441 
 442 
 443 
 444 
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MATERIALS AND METHODS 454 
Antibodies and reagents 455 
The following primary antibodies were used in this study: PE anti-human CD14 (Clone: M5E2) 456 
(BioLegend, CA, USA), MAb 15.2.3 against chlamydial LPS (45), PAb198 against C. pneumoniae 457 
outer membrane (46), Anti-MRP8 (S100A8) (Abcam, UK), Anti-LAMP1 (Sino Biological, China), 458 
Polyclonal Rabbit Anti-Human C3c (Agilent Technologies, Glostrup, Denmark), Polyclonal Rabbit 459 
Anti-Human C4c (Agilent) and Monoclonal Mouse Anti-Human C5b-9 (clone aE11, Agilent). 460 
The following secondary antibodies were used in this study: Goat anti human IgG-, Goat anti rabbit 461 
and Goat anti mouse antibody conjugated to 10 nm colloidal gold (British BioCell, Cardiff, UK) was 462 
used for immunoelectron microscopy. Horseradish peroxidase conjugated Affinipure Goat Anti-Human 463 
Fcγ-specific IgG was used for ELISA. Anti-Rabbit IgG conjugated to alkaline phosphatase was used 464 
for western blotting (Sigma Aldrich, MO, USA). FITC-conjugated Goat Anti-Human IgG, Fcγ 465 
fragment specific (Jackson ImmunoResearch, Cambridge, UK), Alexa Fluor® (AF) 555 goat anti-466 
rabbit, AF555 goat anti-mouse and AF647 goat anti-rabbit (Invitrogen, Thermo Fisher Scientific, MA, 467 
USA) were used for immunofluorescence staining. 468 
TMB/ONE (3,3’,5, 5’-tetramethylbenzidine) and BCIP/NBT (5-bromo-4-chloro-3-indolyl phosphate/ 469 
Nitro Blue Tetrazolium) were purchased from Kementec (Kementec, Taastrup, Denmark) and used for 470 
ELISA and western blotting, respectively. 471 
 472 
 473 
 474 
 on A
pril 15, 2020 at A
alborg U
niversity Library
http://iai.asm
.org/
D
ow
nloaded from
 
23 
 
Cell lines and culture 475 
BHK- and HeLa cell lines were purchased from the American Type Culture Collection (ATCC, VA, 476 
USA) and cultured in complete medium consisting of RPMI 1640 supplemented with 5% fetal calf 477 
serum (FCS), and 0.01 mg/ml gentamicin and maintained at 37°C and 5% CO2. Cell lines were tested 478 
free of mycoplasma by Hoechst (33258) staining.  479 
 480 
Bacterial organism and propagation 481 
C. pneumoniae (CDC/CWL-029/VR1310) was purchased from ATCC and cultivated in Baby Hamster 482 
kidney (BHK) cells in complete medium added 2 µg/ml cycloheximide and 0.1% glucose. The infected 483 
cells were cultured at 37°C and 5% CO2 for 72 hours. C. pneumoniae EBs were purified by density 484 
gradient centrifugation as previously described (46). Mock inoculum was prepared by processing 485 
uninfected BHK cells in parallel with infected cells. 486 
 487 
Serum samples 488 
Serum was obtained from 10 healthy volunteers at Aalborg University, Denmark. Blood was drawn by 489 
venipuncture and collected in S-Monovette® serum tubes (Sarstedt, Nümbrecht, Germany) and serum 490 
was isolated immediately according to manufactures instructions. Isolated serum was immediately 491 
stored on ice before freezing at -80 °C for later use.  Serum heat inactivation was done for 30 min at 492 
56°C. Serum containing anti-C. pneumoniae IgG is denoted “immune serum” and serum without anti-493 
C. pneumoniae IgG is denoted “non-immune serum”. Throughout this paper the following 494 
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abbreviations will be used described the different sera: NHS+: Immune serum, NHS-: Non-immune 495 
serum, HIHS+: heat-inactivated immune serum and HIHS-: heat-inactivated non-immune serum. 496 
All protocols were approved by the Regional ethics committee of Region Nordjylland (N-20150073) 497 
and all experiments were carried according to the Declaration of Helsinki. All participants gave written 498 
informed consent to participate in the study.   499 
 500 
ELISA 501 
C. pneumoniae specific IgG was measured using Chlamydia pneumoniae-IgG ELISA Medac plus 502 
(Medac, Wedel, Germany) using C. pneumoniae outer membrane complex as antigen. Absorbance 503 
were measured at 450 nm on a SunriseTM microplate reader (Tecan, Mannedorf, Switzerland). 504 
 505 
Immunofluorescence validation of serum reactivity 506 
HeLa cell monolayers, seeded on coverslips, were infected with 5x105 inclusion forming units (IFU) C. 507 
pneumoniae by centrifugation at 1000 x g for 30 min at 37°C followed by 30 min incubation at 37°C 508 
and 5% CO2.  Medium containing extracellular bacteria was removed and cells were incubated in 509 
complete medium added 2 µg/ml cycloheximide and 0.1% glucose for 48 hours and subsequently fixed 510 
in 3.7% formaldehyde for 20 min at 4 °C. Cells were permeabilized in ice cold methanol for 10 min, 511 
blocked in 0.5% bovine serum albumin (BSA) for 15 min at 37°C and incubated with serial dilutions of 512 
immune- and non-immune serum for 30 min at 37°C. Cells were washed three times in PBS and 513 
incubated with FITC-conjugated anti-human IgG secondary antibody diluted 1:200 in 0.1% BSA in 514 
PBS for 30 min at 37°C. Cells were washed three times in PBS and counter stained with using 2 µM 515 
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To-Pro-3 Iodide (Invitrogen, Thermo Fisher Scientific) for 20 min at room temperature. Cells were 516 
imaged using a Leica TCS SP5 confocal laser scanning microscope with a HCX PL Apo 63x/1.40 and 517 
CX PL Apo 100x/1.47 objective (Leica Microsystems, Wetzlar, Germany). 518 
 519 
Immunogold-labeling and transmission electron microscopy (TEM) 520 
Purified C. pneumoniae EBs were incubated in 50% NHS or HIHS for 30 min at 37°C and washed 521 
three times in PBS with centrifugation at 15.000 x g, for 15 min at 4°C between each wash. Processing 522 
and immunogold-labeling of bacteria for TEM was performed as previously described (47). Briefly, 523 
serum coated (NHS or HIHS) C. pneumoniae EBs were added to carbon coated 400-mesh glow-524 
discharged nickel grids and washed three times in PBS before blocking in 1% ovalbumin (Sigma-525 
Aldrich) in PBS (pH 6.5). To determine binding of human antibodies to the chlamydial surface, grids 526 
were incubated for 30 min at 37°C with Goat anti human IgG conjugated to 10 nm colloidal gold 527 
diluted 1:25 in 0.5% ovalbumin in PBS. To determine complement binding. samples were incubated 528 
with primary antibodies (anti-C3c, 1:200; anti-C4c, 1:200; anti-C5b-9, 1:20) diluted in 0.5% ovalbumin 529 
in PBS for 30 min at 37°C. Grids were washed in three drops of PBS and subsequently incubated for 530 
30 min at 37°C with secondary antibodies (Goat anti rabbit or Goat anti mouse antibody conjugated to 531 
10 nm colloidal gold) diluted 1:25 in 0.5% ovalbumin in PBS. The grids were washed in three drops 532 
PBS, incubated in three drops of 0.5% cold fish gelatin in PBS and negatively stained with 0.5% 533 
phosphotungstic acid (PTA). Grids were blotted dry on filter paper and investigated using a Jeol 1010 534 
transmission electron microscope (Jeol, Tokyo, Japan). Gold-deposition was quantified as previously 535 
described (47). Briefly, a minimum of seven random fields were imaged for each grid containing at 536 
least 12 chlamydial organisms in total. For each chlamydial organism, gold particles on the bacteria 537 
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and in the background were counted and the density of deposition was calculated for both (gold per 538 
area). From these numbers, a bacteria-to-background ratio was calculated to quantitatively describe 539 
bacterial gold deposition relative to background deposition. From these ratios the median and 540 
interquartile ranges (IQR) were calculated for each sample. 541 
 542 
Western blotting 543 
SDS-PAGE and western blotting were performed essentially according to Lausen et al. (47). Briefly, 544 
purified C. pneumoniae EBs were incubated in 50% serum for 30 minutes at 37°C and unbound 545 
complement was removed by washing three times in PBS with centrifugation at 15,000 x g for 15 min 546 
between each wash. The chlamydial pellet was lysed in SDS Sample buffer + 5% β-mercaptoethanol 547 
and proteins were separated on an 8 % polyacrylamide gel. Proteins were blotted on to a nitrocellulose 548 
membrane (GE Healthcare Life Sciences IL, USA) in Tris-Glycine buffer (25 mM Tris, 192mM 549 
glycine) + 20% methanol for two hours at 100 V using a TE22 Mighty Small Transfer Tank (Hoefer, 550 
Inc., Holliston, MA).  551 
Membranes were blocked for 30 min at 37°C in 3% gelatin in Tris-buffered saline (TBS). Antibodies 552 
diluted in TBS + 0.05% Tween-20 (TBST) + 0.2% gelatin were added to the membranes and left for 553 
incubation for one hour at 37°C. Blots were washed three times in TBST and incubated with alkaline 554 
phosphatase-conjugated secondary antibody for one hour at 37°C. Antigen-antibody complexes were 555 
visualized by adding BCIP/NBT (Kementec) alkaline phosphatase substrate.  556 
 557 
 558 
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Serum neutralization assay 559 
C. pneumoniae EBs were incubated in RPMI 1640 supplemented with 10% human serum for 30 min at 560 
37°C. Opsonized bacteria (10.8x104 IFU for NHS samples and 1.2x104 IFU for HIHS samples) were 561 
used to infect HeLa cell monolayers as described above. Cells were processed for immunofluorescence 562 
microscopy as described above with minor modifications. PAb198 (1:400) and FITC-conjugated goat 563 
anti-rabbit (1:200) were used as primary and secondary antibodies, respectively, and cell nuclei were 564 
stained with 2 µg/ml DAPI.   565 
The cells were inspected using a Leica LSM550 fluorescence microscope and images were captured 566 
from seven random fields in each sample. All samples were analyzed in duplicates and repeated in 567 
three independent experiments. The number of IFU was enumerated and expressed as percentage of 568 
initial inoculum. Data from the three experiments are expressed as mean ± standard deviation (SD).  569 
 570 
FITC-labelling of bacteria 571 
C. pneumoniae inoculum was suspended in 0.1 M NaHCO3 (pH = 9) and centrifuged for 15 min at 572 
15.000 x g. Fluorescein isothiocyanate isomer 1 (FITC) (Sigma, MO, USA) was added at a 573 
concentration of 0.1 mg/ml in 0.1 M NaHCO3 buffer and bacteria were incubated for one hour 574 
protected from light. The labeled bacteria were washed three times in PBS to remove unbound FITC 575 
and the final bacteria pellet was suspended in sucrose-phosphate buffer (2SP), aliquoted, and stored at -576 
80°C. 577 
 578 
 579 
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Immune cell isolation and culture 580 
Peripheral blood was obtained from two donors (one seropositve and one seronegative) and collected in 581 
S-Monovette (Sarstedt) EDTA tubes. Blood was layered on Polymorphprep™ density gradient medium 582 
(Axis-Shield, Dundee, UK) and centrifuged for 40 min at 300 x g at 20°C. Layers with peripheral 583 
blood mononuclear cells (PBMCs) and polymorphnuclear cells were harvested and collected in the 584 
same tube when used for flow cytometry. The two cell populations were kept separate when used for 585 
immunofluorescence microscopy. Platelets was removed by centrifugation at 120 x g for 10 min at 586 
20°C. Cells were resuspended in complete RPMI 1640 medium.     587 
 588 
Immunofluorescence staining and microscopy of immune cells 589 
For immunofluorescence staining, PBMCs were seeded in 8-well Nunc® Lab-Tek® Chamber™ slides 590 
with a density of 9 x 105 cells/well. Cells were left to adhere for 90 min and non-adherent cells were 591 
removed by washing twice in PBS. Bacteria were added at a multiplicity of infection (MOI) 10 in 592 
RPMI 1640 + 10% human serum.  593 
Non-phagocytized bacteria were removed by washing three times in PBS and cells were processed for 594 
immunofluorescence staining as described above. PAb198 (1:400), anti-LAMP1 (1:400), anti-S100A8 595 
(1:300) and MAb 15.2.3 (1:20) were used as primary antibodies and AF555-conjugated goat anti-596 
mouse, AF555-conjugated goat anti-rabbit and AF647-conjugated goat anti-rabbit were used as 597 
secondary antibodies in an 1:200 dilution. Cell nuclei were stained using 2 µM To-Pro-3 Iodide 598 
(Invitrogen, Thermo Fisher Scientific). Cells were imaged using a Leica TCS SP5 confocal laser 599 
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scanning microscope with a CX PL Apo 100x/1,47 objective (Leica Microsystems).  600 
 601 
Phagocytosis assay 602 
FITC-labeled C. pneumoniae EBs were opsonized in RPMI 1640 + 10% human serum for 15 min at 603 
37°C. Bacteria (1x107 or 1x106 bacteria/tube) and immune cells (1x106 cells/tube) were mixed in 5 ml 604 
polypropylene tubes (MOI=10 and MOI=1, respectively) and co-incubated for 30 min at 37°C and cells 605 
were subsequently processed for flow cytometry.  606 
 607 
Flow cytometry 608 
Cells were washed in cold PBS + 0.05% sodium azide to remove non-phagocytized bacteria. Fc-609 
receptors were blocked using 20 µg/ml human IgG (Sigma) for 15 min at 4°C. Primary fluorochrome-610 
conjugated antibodies, diluted in PBS + 0.05% sodium azide + 0.01% BSA, were added and cells were 611 
stained for 30 min at room temperature. Unbound antibody was removed by washing in PBS and cell 612 
viability was assessed using eBioscienceTM Fixable Viability dye eFluorTM 450 according to 613 
manufacturers’s instructions. The cells were washed twice in PBS and fixed in 1% formaldehyde for 20 614 
min at 4°C and analyzed on a CytoFLEX flow cytometer (Beckman Coulter, CA, USA). 615 
 616 
IgG purification 617 
Serum from one seropositive donor was mixed 1:1 with binding buffer (1 M glycine, 150 mM NaCl, 618 
pH 8.5) and the serum IgG fraction was isolated on an affinity chromatography column packed with 619 
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GammaBind Plus protein G Sepharose (GE Healthcare). Bound IgG was eluted from the column using 620 
elution buffer containing 100 mM glycine-HCl pH 2.7 and collected in 25 fractions in tubes containing 621 
1 M Tris-HCl pH 9 to restore neutral pH. The protein concentration in each fraction was determined 622 
using PierceTM BCA Protein Assay Kit (Thermo Scientific) according to manufacturer’s instruction.   623 
 624 
Intracellular survival assay 625 
PBMCs and neutrophils were co-incubated with bacteria as described above. Cells were washed three 626 
times in PBS to remove non-phagocytized bacteria. The cell pellet was suspended in 2SP buffer and 627 
cells were lysed by ultrasonication to liberate ingested bacteria. The cell lysates were used to infect 628 
HeLa cells and IFU were quantified from duplicate samples in three independent experiments as 629 
described above. 630 
 631 
Data analysis 632 
Flow cytometry data were analyzed using FlowLogic™ v.7.2.1 (Inivai Technologies, Mentone 633 
Victoria, Australia). One-way ANOVA with Tukey’s post hoc or Welch ANOVA with Games-Howell 634 
multiple comparison test was used to investigate differences between multiple means. Differences 635 
between means from two independent groups were investigated using student’s independent t-test or 636 
Welch’s t-test. All statistical analyses were performed in SPSS Statistics 25 (IBM, Armonk, NY, 637 
USA).  638 
 639 
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FIGURE LEGENDS 816 
Figure 1 817 
Complement opsonization of C. pneumoniae in non-immune serum. Purified C. pneumoniae EBs were incubated 818 
in A) non-immune serum (NHS-) or B) heat-inactivated non-immune serum (HIHS-) and analyzed by 819 
immunoelectron microscopy (IEM) using anti-C3c and anti-rabbit 10 nm colloidal gold as primary and 820 
secondary antibodies, respectively. C) Gold deposition on each bacterium was quantified relative to the 821 
background gold level for each condition (NHS- and HIHS-). D) Purified C. pneumoniae EBs were subjected to 822 
western blot analysis and labeled against C3c. C. pneumoniae EBs were incubated in E) NHS- or F) HIHS- and 823 
subjected to IEM using anti-C4c as primary antibody. G) Complement C4 deposition was quantified as described 824 
for panel C). H) Western blot analysis of complement C4 deposition on C. pneumoniae incubated in NHS- or 825 
HIHS-. Western blot analysis was repeated three times and representative blots are shown. IEM images were 826 
captured from at least 8 random fields for each sample in one experiment. For each bacterium, a bacterium-to-827 
background gold deposition ratio was calculated and plotted with each dot representing one chlamydial 828 
organism. The median ratio is presented as black lines.  Scale bars indicate 200 nm. 829 
 830 
Figure 2 831 
Antibody- and complement opsonization of C. pneumoniae in immune serum. C. pneumoniae (5x105 IFU/well) 832 
were grown in in HeLa cells for 48 hours and chlamydial inclusions were immunofluorescently stained using 833 
two-fold serial dilutions of A) immune serum or B) non-immune serum as primary antibody. Purified C. 834 
pneumoniae EBs incubated in C) heat-inactivated immune serum (HIHS+) or D) heat-inactivated non-immune 835 
serum (HIHS-) were immuno-labeled with anti-human IgG 10 nm colloidal gold and subjected to immuno-836 
electron microscopy (IEM). E) From IEM images, chlamydial gold deposition, for each bacterium, was 837 
quantified relative to the background gold level. Purified C. pneumoniae EBs were incubated in F) immune 838 
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serum (NHS+) or G) heat-inactivated immune serum (HIHS+) and analyzed by IEM using anti-C3c and anti-839 
rabbit 10 nm colloidal gold as primary and secondary antibodies, respectively. H) Gold deposition in IEM 840 
images was quantified as described for panel E. I) Purified C. pneumoniae EBs were subjected to western blot 841 
analysis and labeled against C3c. J-M) C. pneumoniae were treated as described in panel F-I except bacteria 842 
were labeled using an anti-C4c antibody. For immunofluorescence microcopy, each serum was tested in four 843 
different dilutions and images were captured from five random fields for each dilution. The experiment was 844 
repeated twice. In IEM, a bacterium-to-background gold deposition ratio was calculated for each bacterium and 845 
plotted, with each dot representing one chlamydial organism. The median ratio is presented as black lines. IEM 846 
images were captured from at least 8 random fields for each sample in one experiment. Western blot analysis 847 
was repeated three times and representative blots are shown. Scale bars indicate 10 µm (A,B) and 200 nm 848 
(C,D,F,G,J,K). 849 
 850 
Figure 3 851 
Formation of membrane attack complex (MAC) on C. pneumoniae. Purified C. pneumoniae EBs were incubated 852 
in immune- and non-immune serum and processed for IEM. Images show A) C. pneumoniae incubated in 853 
immune-serum (NHS+) and negatively stained with PTA. B) C. pneumoniae incubated in immune-serum 854 
(NHS+) and negatively stained with PTA and C) C. pneumoniae incubated in non-immune serum (NHS-) and 855 
immuno-gold labeled against C5b-9. Area with disintegrated bacterial morphology was enlarged (hatched boxes) 856 
demonstrating 10 nm pore-like structures (yellow arrowheads) (B+C) in close proximity to gold particles (C). D) 857 
C. pneumoniae incubated in heat-inactivated immune-serum (HIHS+) and immuno-gold labeled against C5b-9. 858 
Anti-mouse 10 nm colloidal gold was used as secondary antibody.  859 
IEM images were used to quantify gold deposition on C. pneumoniae incubated in E) non-immune serum and F) 860 
immune serum. For each chlamydial organism, the gold particle deposition was quantified by calculating a 861 
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bacteria-to-background ratio and the ratios were used to create scatter plots. Each dot represents the ratio from 862 
one chlamydial organism and the black lines show the median ratio.  Scalebars indicate 200 nm. HIHS-: heat-863 
inactivated non-immune serum. 864 
 865 
Figure 4 866 
Serum neutralization of C. pneumoniae EBs. C. pneumoniae inoculum were incubated in immune-serum 867 
(NHS+), non-immune serum (NHS-), heat-inactivated immune-serum (HIHS+), heat-inactivated non-immune 868 
serum (HIHS-) or HIHS- supplemented with 1.5 mg/ml IgG from immune-serum (HIHS-+IgG) for 30 min and 869 
used to infect HeLa cells. HeLa cells were inoculated with 10.8x104 inclusion forming units (IFU) of NHS-870 
opsonized C. pneumoniae and 1.2x104 IFU of HIHS-opsonized C. pneumoniae. IFU were quantified by 871 
immunofluorescence staining of chlamydial inclusions. Images were captured from seven random fields in each 872 
sample using a 16X objective. Data were obtained from duplicate samples from three independent experiments. 873 
All data are presented as mean ± SD. Differences between means were analyzed by Welch’s ANOVA with 874 
Games-Howell multiple comparisons test. P-values < 0.05 were considered statistically significant and denoted 875 
with an asterix (*).  876 
 877 
Figure 5 878 
Opsonophagocytosis of C. pneumoniae in monocytes and neutrophils. The percentage of C. pneumoniae-positive 879 
A) monocytes and B) neutrophils incubated with C. pneumoniae at MOI=10 in non-immune serum was 880 
quantified by flow cytometry. The combined role of complement and anti-C. pneumoniae IgG in C) monocyte 881 
and D) neutrophil phagocytosis was tested using immune serum. Heat-inactivated non-immune serum and heat-882 
inactivated non-immune serum supplemented with the IgG fraction from immune serum was used as control to 883 
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determine the role of IgG in phagocytosis in E) monocytes and F) neutrophils. The percentage of C. 884 
pneumoniae-positive G) monocytes and H) neutrophils incubated with C. pneumoniae at MOI=1 in immune 885 
serum and non-immune serum. Data were obtained from duplicate samples from three independent experiments 886 
except for E) + F) which was obtained from duplicate samples from two independent experiments. A minimum 887 
of 8,000 gated events were obtained from each sample. All data are presented as mean ± SD. One-way ANOVA 888 
with Tukey’s post hoc test, Welch’s ANOVA with Games-Howell multiple comparison test or Welch’s t-test 889 
were used to compare column means. P-values < 0.05 were considered statistically significant and denoted with 890 
an asterix (*).  891 
NHS+: Immune serum, NHS-: Non-immune serum, HIHS+: heat-inactivated immune serum, HIHS-: 892 
heat-inactivated non-immune serum, HIHS-+ IgG: heat-inactivated non-immune serum supplemented 893 
with IgG fraction from immune serum. 894 
 895 
Figure 6 896 
Intracellular neutralization of opsonized C. pneumoniae in PBMCs and neutrophils. C. pneumoniae (MOI=10) 897 
were incubated with A) PBMCs and B) neutrophils under different culture conditions for 30 min and cell lysates 898 
were prepared by ultrasonication. Lysates were used to infect HeLa cell monolayers and inclusion forming units 899 
(IFU) was enumerated after 48 hours by immunofluorescence microscopy. Intracellular localization of C. 900 
pneumoniae in monocytes after 30 min was investigated by immunofluorescence staining and confocal 901 
microscopy of C) C. pneumoniae and D) LAMP1. Frame E) shows an overlay image. F) Monocyte incubated 902 
with mock control. Confocal microscopy was repeated twice for all four (NHS+/NHS-/HIHS+/HIHS-) 903 
conditions and images were captured from five random fields in each sample. 904 
Quantitative data were obtained from duplicate samples from three independent experiments. Data are presented 905 
as mean ± SD. Differences between means were analyzed by Welch’s ANOVA with Games-Howell multiple 906 
comparisons test. P-values < 0.05 were considered statistically significant and denoted with an asterix (*). Scale 907 
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bar indicates 5 µm. NHS+: Immune serum, NHS-: Non-immune serum, HIHS+: heat-inactivated 908 
immune serum, HIHS-: heat-inactivated non-immune serum 909 
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